Postinflammatory hyperpigmentation - Hyperpigmentation Postinflammatory
Hyperpigmentation Postinflammatory (Postinflammatory hyperpigmentation) mangrupikeun kaayaan kulit anu dicirikeun ku paningkatan pigmén dina kulit saatos peradangan kulit. hyperpigmentation postinflammatory (postinflammatory hyperpigmentation) bisa disababkeun ku paparan panonpoé berkepanjangan, peradangan, atawa tatu kulit lianna, kaasup nu patali jeung jerawat. Jalma jeung warna kulit darker biasana leuwih rentan ka hyperpigmentation kalawan kaleuwihan paparan panonpoé.
☆ Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
References
Postinflammatory hyperpigmentation (PIH) mangrupikeun masalah kulit anu sering kajadian saatos radang kulit atanapi tatu. Ieu condong lepas lila sarta leuwih parah di urang jeung warna kulit darker (Fitzpatrick skin types III–VI) . Sanajan éta mindeng meunang hadé sorangan, ieu tiasa nyandak sababaraha waktu, jadi perlakuan anu mindeng diperlukeun pikeun lila. Ngagabungkeun perlakuan béda jalan pangalusna.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
